Melanocortin Receptor 4 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Melanocortin Receptor 4 (MC4R) – Pipeline Review, H1 2020’, provides in depth analysis on Melanocortin Receptor 4 (MC4R) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders, Genetic Disorders, Musculoskeletal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Immunology under development targeting Melanocortin Receptor 4 (MC4R).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

– The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects

– The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aequus BioPharma Inc

Eton Pharmaceuticals Inc

Mallinckrodt Plc

Palatin Technologies Inc

Rhythm Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Melanocortin Receptor 4 (MC4R) - Overview

Melanocortin Receptor 4 (MC4R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development

Aequus BioPharma Inc

Eton Pharmaceuticals Inc

Mallinckrodt Plc

Palatin Technologies Inc

Rhythm Pharmaceuticals Inc

Melanocortin Receptor 4 (MC4R) - Drug Profiles

(liraglutide + setmelanotide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-9610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4-R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocortin Receptor 4 (MC4R) - Dormant Products

Melanocortin Receptor 4 (MC4R) - Discontinued Products

Melanocortin Receptor 4 (MC4R) - Product Development Milestones

Featured News & Press Releases

Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy

Mar 30, 2020: Rhythm Pharmaceuticals completes rolling submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR deficiency obesities

Mar 18, 2020: Rhythm Pharmaceuticals receives orphan drug designation from U.S. FDA for Setmelanotide for the treatment of Alstrom Syndrome

Mar 16, 2020: Mallinckrodt confirms court decision in lawsuit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and provides update related to global opioid settlement and present financing activities

Mar 05, 2020: Data on Acthar Gel (repository corticotropin injection) therapy in immunoglobulin a nephropathy (IgAN) published in Kidney International Reports

Mar 04, 2020: Mallinckrodt announces publication of new data on Acthar Gel (Repository Corticotropin Injection) in rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis published in Open Access Rheumatology: Research and Reviews

Feb 27, 2020: Mallinckrodt to present new data from two studies on Acthar Gel (Repository Corticotropin Injection) therapy in Multiple Sclerosis (MS) relapse at Fifth Annual ACTRIMS Forum 2020

Jan 06, 2020: Rhythm Pharmaceuticals announces leadership transition

Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis

Dec 05, 2019: Rhythm Pharmaceuticals completes enrollment of pivotal cohort in phase 3 clinical trial evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes

Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease

Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting

Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population

Nov 04, 2019: Rhythm Pharmaceuticals announces late-breaking data from phase 3 trials of Setmelanotide in POMC and LEPR deficiency obesities at ObesityWeek 2019

Oct 30, 2019: Rhythm Pharmaceuticals announces late-breaking data presentations at ObesityWeek 2019

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Aequus BioPharma Inc, H1 2020

Pipeline by Eton Pharmaceuticals Inc, H1 2020

Pipeline by Mallinckrodt Plc, H1 2020

Pipeline by Palatin Technologies Inc, H1 2020

Pipeline by Rhythm Pharmaceuticals Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports